212 related articles for article (PubMed ID: 7083197)
1. Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione.
Dao TL
Cancer Res; 1982 Aug; 42(8 Suppl):3338s-3341s. PubMed ID: 7083197
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of estrogen synthesis in human breast tumors by testololactone and bromoandrostenedione.
Budnick RM; Dao TL
Steroids; 1980 May; 35(5):533-41. PubMed ID: 7394858
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies of aromatase inhibitors in relation to the significance of estrogen synthesis in human mammary tumors.
Abul-Hajj YJ
Cancer Res; 1982 Aug; 42(8 Suppl):3373s-3377s. PubMed ID: 6211227
[TBL] [Abstract][Full Text] [Related]
4. In vivo effects of delta 1-testololactone on peripheral aromatization.
Judd HL; Barone RM; Laufer LR; Gambone JC; Monfort SL; Lasley BL
Cancer Res; 1982 Aug; 42(8 Suppl):3345s-3348s. PubMed ID: 7083208
[TBL] [Abstract][Full Text] [Related]
5. Significance of aromatase activity in human breast cancer.
Miller WR; Hawkins RA; Forrest AP
Cancer Res; 1982 Aug; 42(8 Suppl):3365s-3368s. PubMed ID: 7083201
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
7. Biological significance of aromatase activity in human breast tumors.
Tilson-Mallett N; Santner SJ; Feil PD; Santen RJ
J Clin Endocrinol Metab; 1983 Dec; 57(6):1125-8. PubMed ID: 6630410
[TBL] [Abstract][Full Text] [Related]
8. Comparative studies of aromatase inhibitors in cultured human breast cancer cells.
MacIndoe JH; Woods GR; Etre LA; Covey DF
Cancer Res; 1982 Aug; 42(8 Suppl):3378s-3381s. PubMed ID: 7083203
[TBL] [Abstract][Full Text] [Related]
9. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Sonne-Hansen K; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ
Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346
[TBL] [Abstract][Full Text] [Related]
11. 6-Hydroximinoandrostenedione, a new specific inhibitor of estrogen biosynthesis and its effect on T47D human breast cancer cells.
Gervais M; Tan L
Anticancer Res; 1993; 13(2):383-8. PubMed ID: 8517651
[TBL] [Abstract][Full Text] [Related]
12. A new hypothesis based on suicide substrate inhibitor studies for the mechanism of action of aromatase.
Covey DF; Hood WF
Cancer Res; 1982 Aug; 42(8 Suppl):3327s-3333s. PubMed ID: 7083195
[TBL] [Abstract][Full Text] [Related]
13. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
Santen RJ; Santner SJ; Tilsen-Mallett N; Rosen HR; Samojlik E; Veldhuis JD
Cancer Res; 1982 Aug; 42(8 Suppl):3353s-3359s. PubMed ID: 7083200
[TBL] [Abstract][Full Text] [Related]
15. Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model.
Brodie AM; Garrett WM; Hendrickson JR; Tsai-Morris CH
Cancer Res; 1982 Aug; 42(8 Suppl):3360s-3364s. PubMed ID: 6805949
[TBL] [Abstract][Full Text] [Related]
16. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
Reed MJ; Lai LC; Owen AM; Singh A; Coldham NG; Purohit A; Ghilchik MW; Shaikh NA; James VH
Cancer Res; 1990 Jan; 50(1):193-6. PubMed ID: 2293555
[TBL] [Abstract][Full Text] [Related]
17. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
[TBL] [Abstract][Full Text] [Related]
18. Additive effects of aminoglutethimide, testololactone, and 4-hydroxyandrostenedione as inhibitors of aromatase.
Santner SJ; Rosen H; Osawa Y; Santen RJ
J Steroid Biochem; 1984 Jun; 20(6A):1239-42. PubMed ID: 6748639
[TBL] [Abstract][Full Text] [Related]
19. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors: rationale for use following antiestrogen therapy.
Yue W; Santen RJ
Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
